• Explore /
  • Poster
  • / Phase II trial of docetaxel and ramucirumab combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer (HGCSG1903).

Phase II trial of docetaxel and ramucirumab combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer (HGCSG1903).

Abstract Poster

Authors

null

Rika Saito

Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan

Rika Saito , Yasuyuki Kawamoto , Satoshi Yuki , Susumu Sogabe , Masayoshi Dazai , Ayumu Hosokawa , Kentaro Sawada , Atsushi Sato , Michio Nakamura , Kazuteru Hatanaka , Atsushi Ishiguro , Osamu Muto , Yoshiaki Shindo , Yasushi Tsuji , Miki Tateyama , Akira Ueda , Takahide Sasaki , Masaki Katagiri , Naoya Sakamoto , Yoshito Komatsu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

jRCTs011200010

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS4152)

DOI

10.1200/JCO.2021.39.15_suppl.TPS4152

Abstract #

TPS4152

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Sylvie Lorenzen

First Author: Sylvie Lorenzen

First Author: Timothy Jay Price

First Author: Anica Högner